Alzheimer's β-amyloid-induced depolarization of skeletal muscle fibers: Implications for motor dysfunctions in dementia

Cellular Physiology and Biochemistry

Volumn 23, Issue 1-3, 2009, Pages 109-114

  Mukhamedyarov, Marat A ^a   Grishin, Sergey N ^a,b   Yusupova, Elvina R ^a,b   Zefirov, Andrey L ^a   Palotás, András ^c  

^a KAZAN STATE MEDICAL UNIVERSITY   (Russian Federation)

^b KAZAN FEDERAL UNIVERSITY   (Russian Federation)

^c Asklepios Med Bt Private Practice and Research Center   (Hungary)

Author keywords

Alzheimer's disease; Depolarization; Gait disorders; Muscle; amyloid peptide

Indexed keywords

AMYLOID BETA PROTEIN; SODIUM; TETRODOTOXIN;

ALZHEIMER DISEASE; ANIMAL TISSUE; ARTICLE; CELL MEMBRANE DEPOLARIZATION; ELECTROPHYSIOLOGY; FROG; MEMBRANE STEADY POTENTIAL; MOTOR DYSFUNCTION; NONHUMAN; PRIORITY JOURNAL; SKELETAL MUSCLE;

ANURA;

EID: 60549098255     PISSN: 10158987     EISSN: None     Source Type: Journal    
DOI: 10.1159/000204099     Document Type: Article

References (34)

1. Crouch PJ, Harding SM, White AR, Camakaris J, Bushd AI, Masters CL: Mechanisms of Aβ-mediated neurodegeneration in Alzheimer's disease. Int J Biochem Cell Biol 2008;40:181-198.
2. Haass C, Selkoe DJ: Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide. Nat Rev Mol Cell Biol 2007;8:101-112.
3. 2+ -tastrophe. Trends in Neurochemistry Research. Ed: Robert M. Coleman. Nova Science Publishers, Hauppauge, New York, 2005, pp 1-130.
4. Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM: Cerebrospinal fluid tau/β-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol 2007;64:343-349.
5. Koudinov AR, Berezov TT: Alzheimer's amyloid-β is an essential synaptic protein, not neurotoxic junk. Acta Neurobiol Exp 2004;64:71-79.
6. Kuo YM, Kokjohn TA, Watson MD, Woods AS, Cotter RJ, Sue LI, Kalback WM, Emmerling MR, Beach TG, Roher AE: Elevated Aβ42 in skeletal muscle of Alzheimer disease patients suggests peripheral alterations of AβPP metabolism. Am J Pathol 2000;156(3):797-805.
7. Mehta PD, Pirttila T, Mehta SP, Sersen EA, Aisen PS, Wisniewski HM: Plasma and cerebrospinal fluid levels of amyloid β proteins 1-40 and 1-42 in Alzheimer disease. Arch Neurol 2000;57:100-105.
8. Walsh DM, Selkoe DJ: Aβ Oligomers - a decade of discovery. J Neurochem 2007;101:1172-1184.
9. Soininen H, Syrjanen S, Heinonen O, Neittaanmaki H, Miettinen R, Paljarvi L, Syrjanen K, Beyreuther K, Riekkinen P: Amyloid β-protein deposition in skin of patients with dementia. Lancet 1992;339:245.
10. Moussa CE, Fu Q, Kumar P, Shtifman A, Lopez JR, Allen PD, LaFerla F, Weinberg D, Magrane J, Aprahamian T, Walsh K, Rosen KM, Querfurth HW: Transgenic expression of β-APP in fast-twitch skeletal muscle leads to calcium dyshomeostasis and IBM-like pathology. FASEB J 2006;20(12):2165-2167.
11. Kitazawa M, Green KN, Caccamo A, LaFerla FM: Genetically augmenting Aβ42 levels in skeletal muscle exacerbates inclusion body myositis-like pathology and motor deficits in transgenic mice. Am J Pathol 2006;168(6):1986-1997.
12. Palotás A, Penke B, Kemény L, Janka Z, Kálmán J: A chapter in the unity of variety - calcium is the sole author? Brain Res 2004;1000:57-59.
13. Ashenafi S, Fuente A, Criado JM, Riolobos AS, Heredia M, Yajeya J: β-Amyloid peptide 25-35 depresses excitatory synaptic transmission in the rat basolateral amygdala in vitro. Neurobiol Aging 2005 26(4):419-428.
14. Holscher C, Gengler S, Gault VA, Harriott P, Mallot HA: Soluble β-amyloid [25-35] reversibly impairs hippocampal synaptic plasticity and spatial learning. Eur J Pharmacol 2007;561:85-90.
15. Rowan MJ, Klyubin I, Cullen WK, Anwyl R: Synaptic plasticity in animal models of early Alzheimer's disease. Phil Trans R Soc Lond B 2003;358:821-828.
16. Venkitaramani DV, Chin J, Netzer WJ, Gouras GK, Lesne S, Malinow R, Lombroso PJ: β-amyloid modulation of synaptic transmission and plasticity. J Neurosci 2007;27(44):11832-11837.
17. Butterfield DA, Reed T, Newman SF, Sultana R: Roles of amyloid β-peptide-associated oxidative stress and brain protein modifications in the pathogenesis of Alzheimer's disease and mild cognitive impairment. Free Radic Biol Med 2007;43:658-677.
18. Kourie JI: Mechanisms of amyloid-β protein-induced modification in ion transport systems: implications for neurodegenerative diseases. Cell Mol Neurobiol 2001;21(3):173-213.
19. Swanberg MM, Tractenberg RE, Mohs R, Thal LJ, Cummings JL: Executive dysfunction in Alzheimer disease. Arch Neurol 2004;61:556-560.
20. vanHalteren-vanTilborg IA, Scherder EJ, Hulstijn W: Motor-skill learning in Alzheimer's disease: a review with an eye to the clinical practice. Neuropsychol Rev 2007;17:203-212.
21. Wirths O, Bayer TA: Motor impairment in Alzheimer's disease and transgenic Alzheimer's disease mouse models. Genes Brain Behav 2008;7 (Suppl.1):1-5.
22. Garcia N, Santafé MM, Tomàs M, Lanuza MA, Tomàs J: Short-term effects of beta-amyloid 25-35 peptide aggregates on transmitter release in neuromuscular synapses. J Neuropathol Exp Neurol 2008;67(3):250-259.
23. 2+ -channel hypothesis for neuronal death in Alzheimer disease. Mol Cell Biochem 1994;140:119-125.
24. Dougherty JJ, Wu J, Nichols RA: bamyloid regulation of presynaptic nicotinic receptors in rat hippocampus and neocortex. J Neurosci 2003;23(17):6740-6747.
25. Grassi F, Palma E, Tonini R, Amici M, Ballivet M, Eusebi F: Amyloid b 1-42 peptide alters the gating of human and mouse á-bungarotoxin- sensitive nicotinic receptors. J Physiol 2003;547(1):147-157.
26. Martinez-Senac MM, Villalain J, Gomez-Fernandez JC: Structure of the Alzheimer b-amyloid peptide (25-35) and its interaction with negatively charged phospholipid vesicles. Eur J Biochem 1999;265:744-753.
27. Small DH, Maksel D, Kerr ML, Ng J, Hou X, Chu C, Mehrani H, Unabia S, Azari MF, Loiacono R, Aguilar MI, Chebib M: The b-amyloid protein of Alzheimer's disease binds to membrane lipids but does not bind to the a7 nicotinic acetylcholine receptor. J Neurochem 2007;101(6):1527-1538.
28. Magleby KL, Stevens CF: A quantitative description of end-plate currents. J Physiol 1972;223(1):173-197.
29. Wood SJ, Slater CR: Safety factor at the neuromuscular junction. Prog Neurobiol 2001;64:393-429.
30. Fletcher WA, Sharpe JA: Saccadic eye movement dysfunction in Alzheimer's disease. Ann Neurol 1986;20(4):464-471.
31. Buxbaum JN, Ye Z, Reixach N, Friske L, Levy C, Das P, Golde T, Masliah E, Roberts AR, Bartfai T: Transthyretin protects Alzheimer's mice from the behavioral and biochemical effects of Ab toxicity. Proc Natl Acad Sci USA 2008;105(7):2681-2686.
32. Galeazzi L, Galeazzi R, Valli MB, Corder EH, Giunta S: Albumin protects human red blood cells against Ab 25-35-induced lysis more effectively than ApoE. Neuro Report 2002;13(16):2149-2154.
33. Giunta S, Galeazzi R, Valli MB, Corder EH, Galeazzi L: Transferrin neutralization of amyloid-b 25-35 cytotoxicity. Clin Chim Acta 2004;350(1-2):129-136.
34. Caccamo A, Oddo S, Sugarman MC, Akbari Y, LaFerla FM: Age- and region-dependent alterations in Ab-degrading enzymes: implications for Ab-induced disorders. Neurobiol Aging. 2005;26(5):645-654.